Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, has announced the granting of non-statutory stock options to a newly hired non-executive employee. The grant, made on October 1, 2024, covers 6,350 shares of common stock with a per share exercise price of $24.27, matching the closing price on the Nasdaq Global Select Market on the grant date.
The options were granted under the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, and approved by the compensation committee of the board of directors. In accordance with Nasdaq Listing Rule 5635(c)(4), the grant serves as a material inducement for the employee's acceptance of employment. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire on the tenth anniversary of the grant date unless terminated earlier.
Anika Therapeutics, Inc. (NASDAQ: ANIK), un'azienda globale dedicata alla preservazione delle articolazioni nell'ambito dell'ortopedia precoce, ha annunciato il conferimento di opzioni su azioni non statutarie a un nuovo dipendente non esecutivo. Il conferimento, avvenuto il 1° ottobre 2024, riguarda 6.350 azioni ordinarie con un prezzo di esercizio per azione di 24,27 dollari, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market alla data del conferimento.
Le opzioni sono state concesse ai sensi del Piano di Induzione 2021 di Anika Therapeutics, Inc., come modificato, e approvato dal comitato per la compensazione del consiglio di amministrazione. In conformità con la Regola di Quotazione Nasdaq 5635(c)(4), il conferimento funge da incentivo materiale per l'accettazione dell'impiego da parte del dipendente. Il programma di vesting prevede che un terzo delle azioni maturi in corrispondenza di ciascun anniversario del conferimento per i primi tre anni, a condizione di un servizio continuativo. Le opzioni scadranno al decimo anniversario della data di conferimento, salvo cessazione anticipata.
Anika Therapeutics, Inc. (NASDAQ: ANIK), una empresa global dedicada a la preservación de articulaciones en ortopedia de intervención temprana, ha anunciado la concesión de opciones sobre acciones no estatutarias a un nuevo empleado no ejecutivo. La concesión, realizada el 1 de octubre de 2024, abarca 6,350 acciones ordinarias a un precio de ejercicio por acción de $24.27, que coincide con el precio de cierre en el Nasdaq Global Select Market en la fecha de la concesión.
Las opciones se otorgaron bajo el Plan de Inducción 2021 de Anika Therapeutics, Inc., enmendado y aprobado por el comité de compensación de la junta directiva. De acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq, la concesión actúa como un incentivo material para la aceptación del empleo por parte del empleado. El cronograma de adquisición incluye un tercio de las acciones que se adquirirán en cada uno de los primeros tres aniversarios desde la fecha de concesión, siempre que se mantenga el servicio continuo. Las opciones caducarán en el décimo aniversario de la fecha de concesión, a menos que se terminen antes.
아니카 테라퓨틱스, Inc. (NASDAQ: ANIK), 조기 개입 정형외과 분야의 글로벌 관절 보존 회사가 새로 채용된 비상임 직원에게 비상법 주식 옵션을 부여했다고 발표했습니다. 2024년 10월 1일에 이루어진 이번 부여는 주당 24.27달러의 행사 가격으로 6,350주에 해당하며, 부여일의 나스닥 글로벌 셀렉트 마켓 종가와 일치합니다.
이 옵션은 수정된 아니카 테라퓨틱스, Inc. 2021 유인계획에 따라 부여되었으며, 이사회 보상 위원회의 승인도 받았습니다. 나스닥 상장 규칙 5635(c)(4)에 따라, 이 부여는 직원의 고용 수락을 위한 주요 유인이 됩니다. 권리 행사 일정은 부여일의 각 첫 번째 세 번째 기념일마다 1/3의 주식이 확정되며, 지속적인 서비스에 따라 달라집니다. 옵션은 부여일로부터 10년째에 만료되며, 조기 종료되지 않는 한 유효합니다.
Anika Therapeutics, Inc. (NASDAQ: ANIK), une entreprise mondiale de préservation des articulations dans le domaine de l'orthopédie d'intervention précoce, a annoncé l'octroi d'options d'achat d'actions non statutaires à un nouvel employé non-exécutif. L'octroi, effectué le 1er octobre 2024, concerne 6 350 actions ordinaires avec un prix d'exercice par action de 24,27 dollars, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date de l'octroi.
Les options ont été accordées dans le cadre du Plan d'Induction 2021 d'Anika Therapeutics, Inc., tel qu'amendé, et approuvé par le comité de rémunération du conseil d'administration. Conformément à la règle 5635(c)(4) de la liste Nasdaq, l'octroi sert d'incitation matérielle à l'acceptation de l'emploi par l'employé. Le calendrier d'acquisition prévoit qu'un tiers des actions seront acquises lors de chacun des trois premiers anniversaires de la date d'octroi, sous réserve d'un service continu. Les options expireront au dixième anniversaire de la date d'octroi, sauf résiliation anticipée.
Anika Therapeutics, Inc. (NASDAQ: ANIK), ein globales Unternehmen zur Erhaltung von Gelenken im Bereich der Frühintervention in der orthopädischen Medizin, hat die Gewährung von nicht-statutären Aktienoptionen an einen neu eingestellten nicht-executiven Mitarbeiter bekannt gegeben. Die Gewährung, die am 1. Oktober 2024 erfolgte, betrifft 6.350 Stammaktien mit einem Ausübungspreis von 24,27 US-Dollar pro Aktie, der dem Schlusskurs am Nasdaq Global Select Market am Gewährungstag entspricht.
Die Optionen wurden im Rahmen des überarbeiteten Anika Therapeutics, Inc. 2021 Incentive-Plans gewährt und vom Vergütungsausschuss des Vorstands genehmigt. Gemäß der Nasdaq-Listing-Regel 5635(c)(4) dient die Gewährung als wesentlicher Anreiz für die Annahme der Beschäftigung durch den Mitarbeiter. Der Vesting-Plan sieht vor, dass ein Drittel der Aktien an jedem der ersten drei Jahrestage des Gewährungstags, vorbehaltlich einer kontinuierlichen Dienstleistung, vestet. Die Optionen verfallen am zehnten Jahrestag des Gewährungsdatums, sofern sie nicht zuvor beendet werden.
- Anika is attracting new talent with stock options as part of compensation packages
- The company is utilizing its 2021 Inducement Plan to offer competitive employment terms
- None.
BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of
Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
How many stock options did Anika Therapeutics (ANIK) grant on October 1, 2024?
What was the exercise price of the stock options granted by Anika Therapeutics (ANIK) on October 1, 2024?
What is the vesting schedule for the stock options granted by Anika Therapeutics (ANIK) on October 1, 2024?
Under which plan were the stock options granted by Anika Therapeutics (ANIK) on October 1, 2024?
